Navigation Links
WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
Date:11/30/2009

SHANGHAI, Nov. 30 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company with operations in China and the United States, announced that it had been selected to the Deloitte Technology Fast 50 China 2009 list for the fifth consecutive year. The list recognizes the 50 fastest-growing companies in China's technology, media, and telecommunications industries based on revenue growth rates over the previous three years. WuXi PharmaTech is one of only two companies to have won this award for five consecutive years.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

"This recognition is a credit to the dedication and hard work of our employees and the high quality of service they deliver," said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "Through expansion of our capabilities and capacity, both in China and the United States, we are building a broad and fully integrated platform of pharmaceutical R&D services for our customers. We are confident that our continued investment in this platform will generate strong future revenue growth."

    For more information, please contact:

    WuXi PharmaTech (Cayman) Inc.

     Ronald Aldridge (for investors)
     Director of Investor Relations
     Tel:   +1-201-585-2048
     Email: ir@wuxiapptec.com

     Stephanie Liu (for the media)
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-4362
     Email: pr@wuxiapptec.com

SOURCE WuXi PharmaTech (Cayman) Inc.


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
2. WuXi PharmaTech Announces Second-Quarter 2009 Results
3. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting
4. WuXi PharmaTech Schedules Second-Quarter 2009 Earnings Release
5. WuXi PharmaTech Receives Award from BASF
6. WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
7. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
8. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
9. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
10. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
11. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):